GI
DFTX

Gradient Investments’s Definium Therapeutics DFTX Stock Holding History

Gradient Investments’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18
Closed -$56 – 1884
2023
Q3 		$56 Hold
18
– – ﹤0.01% 1739
2023
Q2 		$64 Sell
18
-20
-53% -$69 ﹤0.01% 1705
2023
Q1 		$120 Buy
38
+18
+90% +$60 ﹤0.01% 1430
2022
Q4 		$44 Sell
20
-20
-50% -$56 ﹤0.01% 1458
2022
Q3 		$0 Buy
40
+39
+3,900% +$374 ﹤0.01% 1467
2022
Q2 		$0 Buy
+1
New +$13 ﹤0.01% 1321

Other funds holding DFTX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Gradient Investments's DFTX Position: Q4 2023 in Review

Gradient Investments sold out of Definium Therapeutics (DFTX) in Q4 2023, closing a stake of 18 shares — an estimated $56 sold.

Gradient Investments first reported a position in DFTX in Q2 2022 and held it in 6 quarters. The position peaked at $120 in Q1 2023. 104 funds tracked by Wall St. Rank hold DFTX as of Q4 2023.

  • Gradient Investments reported no remaining Definium Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Gradient Investments sold 18 Definium Therapeutics shares in Q4 2023, an estimated $56.
  • Gradient Investments first reported a position in Definium Therapeutics in Q2 2022 and held it in 6 quarters.
  • Gradient Investments's Definium Therapeutics position peaked at $120 in Q1 2023.
  • 104 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2023.

Based on Gradient Investments's 13F filing for Q4 2023, filed 18 Jan 2024.